Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

WJ Wang, CF Zheng, Z Liu, YH Tan… - European journal of …, 2018 - Wiley Online Library
Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …

Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

W Wang, CF Zheng, Z Liu, Y Tan, X Chen… - European Journal of …, 2018 - hero.epa.gov
OBJECTIVE: This study intended to establish a droplet digital PCR (dd-PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)-positive chronic myeloid …

Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

WJ Wang, CF Zheng, Z Liu, YH Tan… - European journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective This study intended to establish a droplet digital PCR (dd-PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)-positive chronic myeloid …

Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.

WJ Wang, CF Zheng, Z Liu, YH Tan… - European Journal of …, 2018 - europepmc.org
OBJECTIVE: This study intended to establish a droplet digital PCR (dd-PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)-positive chronic myeloid …

Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.

WJ Wang, CF Zheng, Z Liu, YH Tan… - European Journal …, 2018 - search.ebscohost.com
Abstract Abstract: Objective: This study intended to establish a droplet digital PCR (dd‐PCR)
for monitoring minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive …